EURONEXT

Contacts Media

Amsterdam	+31 20 721 4133	Bruxelles	+32 2 620 15 50	
Dublin	+33 1 70 48 24 45	Lisbonne	+351 210 600 614	
Milan	+39 02 72 42 62 12	Oslo	+47 41 69 59 10	
Paris	+33 1 70 48 24 45			

Contact Relations Investisseurs

+33 1 70 48 24 27

Le SPAC eureKING s’introduit sur Euronext Paris

- **150 millions d’euros levés**
- **1er SPAC du secteur de la santé en France et le 1er SPAC européen dédié à la bioproduction**
- **6e cotation d’un SPAC sur Euronext Paris depuis fin 2020**
- **3e cotation d’un SPAC sur les marchés d’Euronext en 2022**

eureKING

KINGS LISTED EURONEXT

Paris – 12 mai 2022 – Euronext célèbre aujourd’hui l’introduction en bourse d’eureKING, premier Special Purpose Acquisition Company (SPAC) français du secteur de la santé dédié à la bioproduction, sur le compartiment professionnel du marché réglementé d’Euronext à Paris (code mnémonique actions : KINGS).

Le SPAC eureKING a été fondé par une équipe internationale d’experts du secteur de la santé, composée de Michael Kloss, précédemment Président et Directeur Général de Panasonic Healthcare, Gérard Le Fur, ancien Directeur Général de Sanofi, Alexandre Mouradian, co-fondateur et administrateur d’eureKARE, Christophe Jean, associé stratégique du fonds de Private Equity Oraxys Environment, Hubert Olivier, Président pour la France et la Belgique du groupe de répartition pharmaceutique et de services de santé McKesson, Rodolphe Besserve, CEO d’eureKARE, par le biais et au nom de son entité affiliée, qui est le premier réseau européen de « biotech studios » spécialisés dans la création, le financement et l’accompagnement de sociétés de biotechnologies innovantes.

L’ambition d’eureKING est de créer une société européenne de bio-CDMO (Contract Development Manufacturing Organization) cotée sur Euronext Paris, acteur majeur dans le domaine de la sous-traitance du façonnage et de la fabrication de produits biopharmaceutiques, afin de soutenir le développement de nouvelles thérapies innovantes.

L'introduction en bourse d'eureKING a été réalisée à la suite de l'admission à la négociation et par cotation directe de 15 000 000 actions de préférence et 15 000 000 de bons de souscription d'actions ordinaires. Le placement a été effectué auprès d’investisseurs qualifiés, pour un montant de 10 euros par unité. Le montant total levé représente 150 millions d’euros.

Michael Kloss, co-fondateur et Directeur Général d’eureKING, a déclaré : *« Nous sommes heureux de présenter l’ambition d’eureKING, dont la mission principale consistera à soutenir le développement en Europe d’un des secteurs les plus prometteurs de l’industrie de la santé, et à faire face à un besoin croissant de réponse aux enjeux de production de l’industrie biopharmaceutique. eureKING a été créé par une équipe de direction internationale composée de talents expérimentés de l'industrie de la santé, 100% dédiée au projet et à sa stratégie de développement, soutenue par un Conseil d’Administration fort de compétences complémentaires* *dans les domaines pharmaceutique et de la finance. Grâce à cette opération, eureKING entend investir dans et acquérir des entreprises spécialisées dans la production et la fabrication de produits biopharmaceutiques pour le compte d'autres sociétés de l'industrie de la santé. »*

Stéphane Boujnah, Directeur Général et Président du Directoire d'Euronext, a commenté : « *Nous sommes heureux d'accueillir aujourd'hui le SPAC eureKING sur les marchés d'Euronext. Ce mode de financement innovant sera très pertinent pour répondre aux besoins des projets ambitieux d'eureKING dans le domaine de la santé, un secteur dont les investissements en innovation sont cruciaux en vue de la période post-covid. eureKING bénéficiera de la profondeur de marché d'Euronext qui dispose de plus grand bassin de liquidités en Europe. Euronext, place de cotation favorite pour les SPAC français et européens, a accueilli en 2021 près de 50% des SPAC cotés en Europe sur ses marchés* ».

Légende : Michael Kloss, co-fondateur et Directeur Général d'eureKING, a sonné la cloche ce matin, aux côtés de son équipe et en présence de Delphine d'Amarzit, Présidente-Directrice Générale d'Euronext Paris, lors d'une cérémonie pour célébrer l'introduction en bourse d'eureKING.

CONTACT EURONEXT

Sarah Mound (Paris)	+33 1 70 48 24 45	parispressoffice@euronext.com

CONTACT EUREKING

Nicolas Merigeau	+33 (0)1 44 71 94 98	nmerigeau@newcap.fr
Arthur Rouillé	+33 (0)1 44 71 00 15	arouille@newcap.fr

A propos d'eureKING

Fondée en mars 2022, eureKING est une SPAC (Special Purpose Acquisition Company) française constituée dans le but d'acquérir des sociétés européennes dans le domaine de la bioproduction, avec l'ambition de créer un bio-CDMO leader en Europe capable de répondre aux besoins en sous-traitance croissants de cette industrie. eureKING a fait le choix de se concentrer sur trois segments hautement spécialisés et stratégiques de l'industrie biopharmaceutique : la production de produits biologiques, en particulier les nouvelles générations d'anticorps monoclonaux ou de protéines complexes, la production de thérapies cellulaires et géniques et la production de produits biothérapeutiques vivants (avec des applications dans le domaine du microbiome). Conduite par une équipe de direction internationale composée de talents expérimentés de l'industrie de la santé, 100% dédiée au projet eureKING et à sa stratégie de développement, et soutenue par un Conseil d'administration fort de compétences complémentaires dans les domaines pharmaceutique et de la finance, eureKING vise le développement et la promotion à l'échelle internationale du secteur prometteur de la bioproduction en Europe.

A propos d'Euronext

Euronext est un groupe leader d'infrastructure de marché pan-européen, connectant les économies européennes aux marchés financiers mondiaux, pour accélérer l'innovation et la croissance durable. Il opère en Belgique, en France, en Irlande, en Italie, en Norvège, aux Pays-Bas et au Portugal. Avec près de 2000 émetteurs et représentant une capitalisation boursière totale de près de 6 600 milliards d'euros à fin March 2022, il dispose d'une franchise inégalée d'indices de premier ordre et d'une solide base de clients diversifiés nationaux et internationaux. Euronext gère des marchés au comptant et dérivés, réglementés et transparents et représente le plus grand centre de cotation d'obligations et de fonds au monde. Son offre recouvre des produits variés tels que les actions, les changes, les ETF (Exchange Traded Funds), les warrants et certificats, les obligations, les dérivés sur actions, les dérivés sur matières premières et les indices. Le Groupe opère une chambre de compensation de classes d'actifs variés via Euronext Clearing, et des services de conservation et de règlement-livraison de titres via les dépositaires centraux d'Euronext Securities au Danemark, en Italie, en Norvège et au Portugal. Euronext met également à profit son expertise en fournissant des solutions technologiques et des services administrés à des tiers. En complément de son principal marché réglementé, Euronext gère également des marchés de croissance qui facilitent et simplifient la cotation des petites et moyennes entreprises. Suivez les dernières actualités d'Euronext sur Twitter(twitter.com/euronext) et LinkedIn (linkedin.com/euronext)

Disclaimer

This press release is not a prospectus but an advertisement provided for information purposes only. It does not constitute and should not be deemed to constitute an offer to the public of securities by eureKING, nor a solicitation of the public relating to an offer of any kind whatsoever in any country, including France.

A prospectus (the "Prospectus") has been approved by the *Autorité des marchés financiers* (AMF) on May 6, 2022, under no.22-134 solely for the purpose of listing of eureKING securities on the professional segment (*compartiment professionnel*) of the regulated market of Euronext Paris. A copy of the Prospectus is available on the AMF's website (www.amf-france.org) and on eureKING's website (www.eureking.com) and may be obtained free of charge from eureKING.

Potential investors should review the risk factors described in the Prospectus.

Investors should not subscribe for or purchase any securities referred to in this press release except on the basis of the information contained in the Prospectus.

The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

Prohibition of sales to European Economic Area, U.K. and Swiss retail investors

The Units(*actions de préférence stipulées rachetables assorties de bons de souscription d'actions ordinaires de la société rachetables*) are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "EEA"), the United Kingdom (the "U.K.") or Switzerland.

For the purpose of the present press release, a "retail investor" means a person who is one (or more) of the following:

(a) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II");

(b) a retail client as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of U.K. domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "EUWA");

(c) a customer within the meaning of Directive 2016/97/EU (as amended, the "Insurance Distribution Directive") where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II;

(d) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (as amended, the "FSMA") and any rules or regulations made under the FSMA to implement the Insurance Distribution Directive, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of U.K. domestic law by virtue of the EUWA (the "U.K. MiFIR");

(e) not a qualified investor as defined in Article 2(e) of the regulation (EU) 2017/1129 of 14 June 2017 (as amended, the "Prospectus Regulation"), including as it forms part of U.K. domestic law by virtue of the EUWA;

(f) not a professional client as defined in Article 4 Paragraph 3 of the Swiss Federal Act on Financial Services ("FinSA").

Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation"), including the PRIIPS Regulation as it forms part of UK domestic law by virtue of the EUWA (the "UK PRIIPS Regulation"), for offering or selling the Units or otherwise making them available to retail investors in the EEA, in the U.K. or in Switzerland has been prepared and therefore offering or selling the Units or otherwise making them available to any retail investor in the EEA, in the U.K. or in Switzerland may be unlawful under the PRIIPs Regulation the UK PRIIPS Regulation, or the FinSA.

MIFID II and U.K. MiFIR product governance

Solely for the purposes of the manufacturer's product approval process, the EEA target market assessments (the "EEA Target Market Assessments") have led to the conclusion that:

(a) in respect of the Units:

(i) the target market is eligible counterparties and professional clients only, each as defined in MiFID II; and

(ii) all channels for distribution to eligible counterparties and professional clients are appropriate;

(b) in respect of the Preferred Shares and the Warrants:

(i) the target market is retail investors, and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and

(ii) all channels for distribution to eligible counterparties and professional clients are appropriate.

Solely for the purposes of each manufacturer's product approval process, the U.K. target market assessments (the "U.K. Target Market Assessments") have led to the conclusion that:

(a) in respect of the Units:

(i) the target market is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook ("COBS"), and professional clients, as defined U.K. MiFIR; and

(ii) all channels for distribution to eligible counterparties and professional clients are appropriate;

(b) in respect of the Preferred Shares and the Warrants:

(i) the target market is (a) retail clients, as defined in point (8) of Article 2 of the Prospectus Regulation as it forms part of U.K. domestic law by virtue of the EUWA, (b) investors who meet the criteria of professional clients as defined in U.K. MiFIR and (c) eligible counterparties as defined in the COBS; and

(ii) all channels for distribution to eligible counterparties and professional clients are appropriate.

Notwithstanding the EEA Target Market Assessments and the U.K. Target Market Assessments, distributors should note that: the price of the Preferred Shares and the Warrants may decline and investors could lose all or part of their investment; the Preferred Shares and the Warrants offer no guaranteed income and no capital protection; and an investment in the Preferred Shares and/or the Warrants is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The EEA Target Market Assessments and the U.K. Target Market Assessments are without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offering.

For the avoidance of doubt, the EEA Target Market Assessments and the U.K. Target Market Assessments do not constitute: (a) assessments of suitability or appropriateness for the purposes of MiFID II or COBS or (b) recommendations to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Units, the Preferred Shares or the Warrants.

Each distributor is responsible for undertaking its own target market assessments in respect of the Units, the Preferred Shares and the Warrants and determining appropriate distribution channels.

France

In France, any offer of eureKING securities is addressed solely to qualified investors, as defined in Article 2(e) of the Prospectus Regulation and in accordance with the provisions of Article L. 411-2, 1° of the French *Code monétaire et financier*.

United Kingdom

This press release does not constitute an offer of securities to the public in the United Kingdom. In the United Kingdom, this press release is for distribution only to and is directed only at (a) "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation as it forms part of U.K. domestic law by virtue of the EUWA which are (b) (i) persons who have professional experience in matters relating to investments falling within the provisions of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) "high net worth entities", "unincorporated associations" and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). This press release must not be acted on or relied on, in the United Kingdom, by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is only available to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this press release must satisfy themselves that it is lawful to do so.

United States of America

This press release and the information it contains does not, and will not, constitute an offer to the public to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, eureKING's securities in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), it being specified that eureKING's securities have not been and will not be registered under the Securities Act and eureKING does not intend to register securities or conduct an offer to the public in the United States.

Switzerland

The offering of eureKING's securities is exempt from the requirement to prepare and publish a prospectus under the Swiss Federal Act on Financial Services ("FinSA") because such offering is made to professional clients within the meaning of the FinSA and eureKING's securities will not be admitted to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. This press release does not constitute a prospectus pursuant to the FinSA, and no such prospectus has been or will be prepared for or in connection with the offering of eureKING's securities.

Canada

This press release and the information it contains do not, and will not, constitute an offer to the public to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, eureKING's securities in any province or territory of Canada.

Securities may not be offered or sold in Canada except in a transaction exempt from the prospectus requirements of applicable Canadian securities laws or pursuant to a prospectus that qualifies those securities in the relevant provinces and territories of Canada, it being specified that the eureKING's securities have not been and will not be qualified by way of prospectus under the securities laws of any province or territory of Canada and eureKING does not intend to qualify any such securities or conduct an offering to the public in Canada.

Israel

The securities offered by this press release have not been approved or disapproved by the Israel Securities Authority (the "ISA"), nor have such securities been registered for sale in Israel. The securities may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus that has been approved by the ISA. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing this press release, nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. This press release and the information it contains do not, and will not, constitute a prospectus under the Israeli Securities Law, 5728-1968, as amended (the "Israeli Securities Law"), and no such prospectus has been or will be filed with or approved by the ISA. In the State of Israel, this press release may be distributed only to, and may be directed only at, and any offer of the securities may be directed only at, (i) to the extent applicable, a limited number of persons in accordance with the Israeli Securities Law and (ii) investors listed in the first addendum to the Israeli Securities Law (the "Addendum") consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and "qualified individuals", each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.